Posted by Michael Wonder on 04 Dec 2018
Medicines for severe asthma and growth hormone deficiency listed on the PBS
1 December 2018 - The Australian Government will list new medicines for severe asthma, and severe growth hormone deficiency on the PBS, saving patients up to $21,000 a year.
The Liberal National Government will list new medicines for severe asthma, and severe growth hormone deficiency on the PBS, saving patients up to $21,000 a year.
From today Fasenra (benralizumab), a new treatment option for patients with uncontrolled severe eosinophilic asthma, will be available on the PBS.
Around 670 patients a year will now be able to access this medicine, which would cost more than $21,000 per year of treatment without the PBS subsidy. When this medicine is subsidised under the PBS, patients will pay 39.50 per script or just $6.40 a script for concessional patients.
